Hudson Bay Capital Management
SGMO

Hudson Bay Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Hudson Bay Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50,000
Closed -$207K – 1350
2022
Q2 		$207K Hold
50,000
– – ﹤0.01% 1004
2022
Q1 		$291K Buy
+50,000
New +$297K ﹤0.01% 899

Other funds holding SGMO

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hudson Bay Capital Management's SGMO Position: Q2 2025 in Review

Hudson Bay Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2025, closing a stake of 42,370 shares — an estimated $27.8K sold.

Hudson Bay Capital Management first reported a position in SGMO in Q2 2017 and held it in 27 quarters. The position peaked at $5.62M in Q4 2020. 114 funds tracked by Wall St. Rank hold SGMO as of Q2 2025.

  • Hudson Bay Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 42,370 SANGAMO THERAPEUTICS INC shares in Q2 2025, an estimated $27.8K.
  • Hudson Bay Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2017 and held it in 27 quarters.
  • Hudson Bay Capital Management's SANGAMO THERAPEUTICS INC position peaked at $5.62M in Q4 2020.
  • 114 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2025.

Based on Hudson Bay Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.